胆道恶性肿瘤系统治疗与局部治疗的现状及进展

郑康炼; 王晓东

doi:10.3969/j.issn.1001-5256.2022.02.046

胆道恶性肿瘤系统治疗与局部治疗的现状及进展

DOI: 10.3969/j.issn.1001-5256.2022.02.046

郑康炼,
王晓东^,

北京大学肿瘤医院介入治疗科，北京 100142

基金项目:

北京市医院管理中心临床医学发展专项 (ZYLX202117)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：郑康炼负责文献搜索和整理，撰写论文；王晓东负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
王晓东, wangxde@gmail.com

计量
- 文章访问数: 664
- HTML全文浏览量: 471
- PDF下载量: 105
- 被引次数: 0
出版历程
- 收稿日期: 2021-06-18
- 录用日期: 2021-07-20
- 出版日期: 2022-02-20

Systemic therapy and local therapy for biliary tract cancer: Current status and advances

Kanglian ZHENG,
Xiaodong WANG^,

Department of Interventional Therapy, Peking University Cancer Hospital, Beijing 100142, China

Research funding:

Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support (ZYLX202117)

More Information

Corresponding author: WANG Xiaodong, wangxde@gmail.com

摘要

摘要: 胆道恶性肿瘤是一种预后极差的消化系统恶性肿瘤，近年来随着各种治疗方法的进展，胆道恶性肿瘤患者的生存时间得以延长。本文就胆道恶性肿瘤的手术治疗、全身治疗、放射治疗以及介入治疗的现状和进展进行系统综述，以期为临床上胆道恶性肿瘤的治疗提供参考。
- 胆道恶性肿瘤 /
- 外科手术 /
- 治疗学 /
- 介入治疗
Abstract: Biliary tract cancer (BTC) is a digestive system malignancy with extremely poor prognosis, and the survival time of patients with BTC has been prolonged with the development of various treatment methods in recent years. This article reviews the current status and advances in surgery, systemic therapy, radiotherapy, and interventional therapy for BTC, so as to provide a reference for the treatment of BTC in clinical practice.
- Biliary Tract Cancer /
- Surgical Procedures, Operative /
- Therapeutics /
- Interventional Therapy

HTML全文

参考文献(60)

[1]	PARK J, KIM MH, KIM KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: A large-scale observational study[J]. Gut Liver, 2009, 3(4): 298-305. DOI: 10.5009/gnl.2009.3.4.298.
[2]	DUFFY A, CAPANU M, ABOU-ALFA GK, et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC)[J]. J Surg Oncol, 2008, 98(7): 485-489. DOI: 10.1002/jso.21141.
[3]	RIZVI S, KHAN SA, HALLEMEIER CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies[J]. Nat Rev Clin Oncol, 2018, 15(2): 95-111. DOI: 10.1038/nrclinonc.2017.157.
[4]	SCHMIDT MA, MARCANO-BONILLA L, ROBERTS LR. Gallbladder cancer: Epidemiology and genetic risk associations[J]. Chin Clin Oncol, 2019, 8(4): 31. DOI: 10.21037/cco.2019.08.13.
[5]	BRIDGEWATER JA, GOODMAN KA, KALYAN A, et al. Biliary tract cancer: Epidemiology, radiotherapy, and molecular profiling[J]. Am Soc Clin Oncol Educ Book, 2016, 35: e194-e203. DOI: 10.1200/EDBK_160831.
[6]	SKIPWORTH JR, KEANE MG, PEREIRA SP. Update on the management of cholangiocarcinoma[J]. Dig Dis, 2014, 32(5): 570-578. DOI: 10.1159/000360507.
[7]	CHUN YS, JAVLE M. Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma[J]. Cancer Control, 2017, 24(3): 1073274817729241. DOI: 10.1177/1073274817729241.
[8]	ZHAO XF, LI GM. Diagnosis and treatments for intrahepatic cholangciocarcinoma[J/CD]. Chin J Hepat Surg(Electronic Edition), 2021, 10(1): 6-9. DOI: 10.3877/cma.j.issn.2095-3232.2021.01.002. 赵晓飞, 栗光明. 肝内胆管细胞癌的诊治[J/CD]. 中华肝脏外科手术学电子杂志, 2021, 10(1): 6-9. DOI: 10.3877/cma.j.issn.2095-3232.2021.01.002.
[9]	CHEN TA, XIONG YF, YANG FC, et al. Research progress and dispute on surgical treatments for perihilar cholangiocarcinoma[J/CD]. Chin J Hepat Surg(Electronic Edition), 2021, 10(2): 133-138. DOI: 10.3877/cma.j.issn.2095-3232.2021.02.004. 陈泰安, 熊永福, 杨发才, 等. 肝门部胆管癌外科治疗进展和争议[J/CD]. 中华肝脏外科手术学电子杂志, 2021, 10(2): 133-138. DOI: 10.3877/cma.j.issn.2095-3232.2021.02.004.
[10]	KIM HS, PARK JW, KIM H, et al. Optimal surgical treatment in patients with T1b gallbladder cancer: An international multicenter study[J]. J Hepatobiliary Pancreat Sci, 2018, 25(12): 533-543. DOI: 10.1002/jhbp.593.
[11]	KOBAYASHI A, MIWA S, NAKATA T, et al. Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma[J]. Br J Surg, 2010, 97(1): 56-64. DOI: 10.1002/bjs.6788.
[12]	JUNG SJ, WOO SM, PARK HK, et al. Patterns of initial disease recurrence after resection of biliary tract cancer[J]. Oncology, 2012, 83(2): 83-90. DOI: 10.1159/000339695.
[13]	MIYAZAKI Y, KOKUDO T, AMIKURA K, et al. Survival of surgery for recurrent biliary tract cancer: A single-center experience and systematic review of literature[J]. Jpn J Clin Oncol, 2017, 47(3): 206-212. DOI: 10.1093/jjco/hyw182.
[14]	BEN-JOSEF E, GUTHRIE KA, EL-KHOUEIRY AB, et al. SWOG S0809: A phase Ⅱ intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. J Clin Oncol, 2015, 33(24): 2617-2622. DOI: 10.1200/JCO.2014.60.2219.
[15]	PRIMROSE JN, FOX RP, PALMER DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study[J]. Lancet Oncol, 2019, 20(5): 663-673. DOI: 10.1016/S1470-2045(18)30915-X.
[16]	REN B, GUO Q, YANG Y, et al. A meta-analysis of the efficacy of postoperative adjuvant radiotherapy versus no radiotherapy for extrahepatic cholangiocarcinoma and gallbladder carcinoma[J]. Radiat Oncol, 2020, 15(1): 15. DOI: 10.1186/s13014-020-1459-x.
[17]	LE ROY B, GELLI M, PITTAU G, et al. Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma[J]. Br J Surg, 2018, 105(7): 839-847. DOI: 10.1002/bjs.10641.
[18]	JUNG JH, LEE HJ, LEE HS, et al. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma[J]. World J Gastroenterol, 2017, 23(18): 3301-3308. DOI: 10.3748/wjg.v23.i18.3301.
[19]	VALLE J, WASAN H, PALMER DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med, 2010, 362(14): 1273-1281. DOI: 10.1056/NEJMoa0908721.
[20]	MORIZANE C, OKUSAKA T, MIZUSAWA J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: The FUGA-BT (JCOG1113) randomized phase Ⅲ clinical trial[J]. Ann Oncol, 2019, 30(12): 1950-1958. DOI: 10.1093/annonc/mdz402.
[21]	KIM ST, KANG JH, LEE J, et al. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: A multicenter, open-label, randomized, phase Ⅲ, noninferiority trial[J]. Ann Oncol, 2019, 30(5): 788-795. DOI: 10.1093/annonc/mdz058.
[22]	SHROFF RT, JAVLE MM, XIAO L, et al. Gemcitabine, cisplatin, and nab-Paclitaxel for the treatment of advanced biliary tract cancers: A phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(6): 824-830. DOI: 10.1001/jamaoncol.2019.0270.
[23]	LAMARCA A, PALMER DH, WASAN HS, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial[J]. Lancet Oncol, 2021, 22(5): 690-701. DOI: 10.1016/S1470-2045(21)00027-9.
[24]	FURUSE J, GOYAL L, MERIC-BERNSTAM F, et al. Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2[C]. European Society for Medical Oncology, 2020.
[25]	JAVLE MM. Final results from a phase Ⅱ study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement[C]. Gastrointestinal Cancers Symposium: American Society of Clinical Oncology, 2021.
[26]	ABOU-ALFA GK, MACARULLA T, JAVLE MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): A multicentre, randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Oncol, 2020, 21(6): 796-807. DOI: 10.1016/S1470-2045(20)30157-1.
[27]	SUBBIAH V, LASSEN U, ÉLEZ E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): A phase 2, open-label, single-arm, multicentre basket trial[J]. Lancet Oncol, 2020, 21(9): 1234-1243. DOI: 10.1016/S1470-2045(20)30321-1.
[28]	HARDING JJ, CLEARY JM, QUINN DI, et al. Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase Ⅱ SUMMIT 'basket' trial[J]. J Clini Oncol, 2021, 39(3_suppl): 320-320. DOI: 10.1200/JCO.2021.39.3_suppl.320
[29]	DEMOLS A, BORBATH I, EYNDE MVD, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tumors: A randomized double-blinded placebo-controlled phase Ⅱ trial[J]. J Clini Oncol, 2019, 37(4_suppl): 345. DOI: 10.1200/JCO.2019.37.4_suppl.345
[30]	PIHA-PAUL SA, OH DY, UENO M, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies[J]. Int J Cancer, 2020, 147(8): 2190-2198. DOI: 10.1002/ijc.33013.
[31]	KIM RD, CHUNG V, ALESE OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer[J]. JAMA Oncol, 2020, 6(6): 888-894. DOI: 10.1001/jamaoncol.2020.0930.
[32]	OH DY, LEE KH, LEE DW, et al. Phase Ⅱ study assessing tolerability, efficacy, and biomarkers for durvalumab (D) ±tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-nave advanced biliary tract cancer (aBTC)[J]. J Clini Oncol, 2020, 38(15_suppl): 4520-4520. DOI: 10.1200/JCO.2020.38.15_suppl.4520
[33]	VILLANUEVA L, LWIN Z, CHUNG HCC, et al. Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study[J]. J Clini Oncology, 2021, 39(15_suppl): 4080. DOI: 10.1200/JCO.2021.39.15_suppl.4080
[34]	HONG Z. Phase Ⅱ study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers[C]. Gastrointestinal Cancers Symposium: American Society of Clinical Oncology, 2021.
[35]	ZHOU J, FAN J, SHI G, et al. Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase Ⅱ clinical trial[C]. European Society for Medical Oncology, 2020.
[36]	JIAN Z, FAN J, SHI GM, et al. Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial[J]. J Clin Oncol, 2021, 39(15_suppl): 4094. DOI: 10.1200/JCO.2021.39.15_suppl.4094
[37]	ZHANG YF, CAI JQ. Progress in immunotherapy of malignant tumors of biliary tract[J/CD]. Electronic J Liver Tumor, 2021, 8(1): 32-34. DOI: 10.3969/j.issn.2095-7815.2021.01.005. 张业繁, 蔡建强. 胆道恶性肿瘤的免疫治疗进展[J/CD]. 肝癌电子杂志, 2021, 8(1): 32-34. DOI: 10.3969/j.issn.2095-7815.2021.01.005.
[38]	GHAFOORI AP, NELSON JW, WILLETT CG, et al. Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(3): 654-659. DOI: 10.1016/j.ijrobp.2010.06.018.
[39]	TAO R, KRISHNAN S, BHOSALE PR, et al. Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: A retrospective dose response analysis[J]. J Clin Oncol, 2016, 34(3): 219-226. DOI: 10.1200/JCO.2015.61.3778.
[40]	HONG TS, WO JY, YEAP BY, et al. Multi-institutional phase Ⅱ study of high-dose hypofractionated proton beam therapy in patients with localized, unresectable hepatocellular carcinoma and intrahepatic cholangiocarcinoma[J]. J Clin Oncol, 2016, 34(5): 460-468. DOI: 10.1200/JCO.2015.64.2710.
[41]	KOZAK MM, TOESCA D, von EYBEN R, et al. Stereotactic body radiation therapy for cholangiocarcinoma: Optimizing locoregional control with elective nodal irradiation[J]. Adv Radiat Oncol, 2020, 5(1): 77-84. DOI: 10.1016/j.adro.2019.08.003.
[42]	GIORGIO A, GATTI P, MONTESARCHIO L, et al. Intrahepatic cholangiocarcinoma and thermal ablation: Long-term results of an italian retrospective multicenter study[J]. J Clin Transl Hepatol, 2019, 7(4): 287-292. DOI: 10.14218/JCTH.2019.00036.
[43]	BELFIORE MP, REGINELLI A, MAGGIALETTI N, et al. Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: Feasibility, safety and efficacy[J]. Med Oncol, 2020, 37(5): 45. DOI: 10.1007/s12032-020-01360-2.
[44]	KIEFER MV, ALBERT M, MCNALLY M, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: A 2-center study[J]. Cancer, 2011, 117(7): 1498-1505. DOI: 10.1002/cncr.25625.
[45]	SCHIFFMAN SC, METZGER T, DUBEL G, et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: Optimal tolerance and prolonged overall survival[J]. Ann Surg Oncol, 2011, 18(2): 431-438. DOI: 10.1245/s10434-010-1333-4.
[46]	KUHLMANN JB, EURINGER W, SPANGENBERG HC, et al. Treatment of unresectable cholangiocarcinoma: Conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy[J]. Eur J Gastroenterol Hepatol, 2012, 24(4): 437-443. DOI: 10.1097/MEG.0b013e3283502241.
[47]	LIU JB, CHU KJ, LING CC, et al. Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization[J]. Curr Probl Cancer, 2020, 44(6): 100612. DOI: 10.1016/j.currproblcancer.2020.100612.
[48]	YANG GW, ZHAO Q, QIAN S, et al. Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for the treatment of advanced intrahepatic cholangiocarcinoma[J]. Onco Targets Ther, 2015, 8: 1245-1250. DOI: 10.2147/OTT.S84764.
[49]	IBRAHIM SM, MULCAHY MF, LEWANDOWSKI RJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: Results from a pilot study[J]. Cancer, 2008, 113(8): 2119-2128. DOI: 10.1002/cncr.23818.
[50]	BUETTNER S, BRAAT A, MARGONIS GA, et al. Yttrium-90 radioembolization in intrahepatic cholangiocarcinoma: a multicenter retrospective analysis[J]. J Vasc Interv Radiol, 2020, 31(7): 1035-1043. e2. DOI: 10.1016/j.jvir.2020.02.008.
[51]	EDELINE J, TOUCHEFEU Y, GUIU B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial[J]. JAMA Oncol, 2020, 6(1): 51-59. DOI: 10.1001/jamaoncol.2019.3702.
[52]	BOEHM LM, JAYAKRISHNAN TT, MIURA JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma[J]. J Surg Oncol, 2015, 111(2): 213-220. DOI: 10.1002/jso.23781.
[53]	WRIGHT GP, PERKINS S, JONES H, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: A comparison of surgical resection with intra-arterial therapies[J]. Ann Surg Oncol, 2018, 25(1): 83-90. DOI: 10.1245/s10434-017-6110-1.
[54]	WANG X, HU J, CAO G, et al. Phase Ⅱ study of hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced perihilar cholangiocarcinoma[J]. Radiology, 2017, 283(2): 580-589. DOI: 10.1148/radiol.2016160572.
[55]	ZHENG K, WANG X, CAO G, et al. Hepatic arterial infusion chemotherapy with oxaliplatin and 5-fluorouracil for advanced gallbladder cancer[J]. Cardiovasc Intervent Radiol, 2021, 44(2): 271-280. DOI: 10.1007/s00270-020-02661-9.
[56]	MARUMOTO M, YAMASAKI T, MARUMOTO Y, et al. Systemic gemcitabine combined with hepatic arterial infusion chemotherapy with cisplatin, 5-fluorouracil, and isovorin for the treatment of advanced intrahepatic cholangiocarcinoma: A pilot study[J]. Hepatogastroenterology, 2014, 61(129): 162-167.
[57]	CERCEK A, BOERNER T, TAN BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: A phase 2 clinical trial[J]. JAMA Oncol, 2020, 6(1): 60-67. DOI: 10.1001/jamaoncol.2019.3718.
[58]	ZHU HD, GUO JH, HUANG M, et al. Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial[J]. J Hepatol, 2018, 68(5): 970-977. DOI: 10.1016/j.jhep.2017.12.028.
[59]	PARK DH, LEE SS, PARK SE, et al. Randomised phase Ⅱ trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma[J]. Eur J Cancer, 2014, 50(7): 1259-1268. DOI: 10.1016/j.ejca.2014.01.008.
[60]	PEREIRA SP, JITLAL M, DUGGAN M, et al. PHOTOSTENT-02: Porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer[J]. ESMO Open, 2018, 3(5): e000379. DOI: 10.1136/esmoopen-2018-000379.